Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
15 participants
INTERVENTIONAL
2015-08-31
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Specific Aim 1: To compare the baseline to 4 month change in clinical ridge width and height.
Specific Aim 2: To compare the histologic percent of vital and nonvital bone and trabecular space at 4 months.
The primary outcome variable is the change in horizontal ridge width. The secondary outcomes are the change in ridge height and the percent histologic composition of the augmented site.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ridge Augmentation Comparing a Block Allograft to a Demineralized Bone Matrix Allograft.
NCT02127112
Alveolar Ridge Preservation With Putty Allograft vs. Putty Alloplast Graft
NCT05484492
Ridge Augmentation Using Allograft Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth Factor
NCT04954664
Vertical and Horizontal Alveolar Ridge Augmentation Using Autogenous Onlay Blocks Combined With Guided Bone Regeneration Using Native Collagen Membrane in Atrophic Anterior Maxilla.
NCT03895060
The Influence of Bone Allograft Particle Sizes on the Quantity and Quality of New Bone Formation in Grafted Extraction Sockets and Edentulous Ridges
NCT03468998
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Particulate allograft + autogenous bone.
In the test arm of the study the treatment will include a mix of MinerOss CorticoCancellous Particulate allograft + autogenous bone chips.
Particulate allograft + autogenous bone chips
The test arm of this study will include a mix of particulate bone allograft and autogenous bone chips.
Block allograft
The positive control treatment will include a block allograft plus Mineross corticocancellous particulate allograft.
Block allograft
A cancellous block allograft plus corticocancellous particulate allograft will be used as the positive control treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Block allograft
A cancellous block allograft plus corticocancellous particulate allograft will be used as the positive control treatment.
Particulate allograft + autogenous bone chips
The test arm of this study will include a mix of particulate bone allograft and autogenous bone chips.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy person that is at least 18 years old.
* Patient understands and signs an informed consent approved by the University of Louisville Human Studies Committee.
Exclusion Criteria
* Previous head and neck radiation or chemotherapy within the previous 12 months.
* Patients with known allergy to any of the materials that will be used in the study.
* Smokers.
* Patients on oral bisphosphonates \> 3 years or any IV bisphosphonates.
* Patients who are pregnant.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Louisville
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Henry Greenwell
Director of Graduate Periodontics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Henry Greenwell, DMD, MSD
Role: PRINCIPAL_INVESTIGATOR
Director of Graduate Periodontics, School of Dentistry, University of Louisville.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15.0530
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.